We are live on ! Find out more
EVH icon

Evolent Health

243 hedge funds and large institutions have $2.48B invested in Evolent Health in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 102 increasing their positions, 74 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% more repeat investments, than reductions

Existing positions increased: 102 | Existing positions reduced: 74

2.54% more ownership

Funds ownership: 109.03%111.57% (+2.5%)

3% less funds holding

Funds holding: 251243 (-8)

12% less first-time investments, than exits

New positions opened: 45 | Existing positions closed: 51

40% less capital invested

Capital invested by funds: $4.12B → $2.48B (-$1.65B)

43% less funds holding in top 10

Funds holding in top 10: 74 (-3)

58% less call options, than puts

Call options by funds: $10.5M | Put options by funds: $25.1M

Holders
243
Holders Change
-8
Holders Change %
-3.19%
% of All Funds
3.51%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.06%
New
45
Increased
102
Reduced
74
Closed
51
Calls
$10.5M
Puts
$25.1M
Net Calls
-$14.6M
Net Calls Change
-$22.3M
Name Holding Trade Value Shares
Change
Change in
Stake
American Century Companies
26
American Century Companies
Missouri
$25.1M -$6.3M -246,640 -16%
Fuller & Thaler Asset Management
27
Fuller & Thaler Asset Management
California
$24.6M +$6M +234,897 +22%
Millennium Management
28
Millennium Management
New York
$24.1M -$4.94M -193,535 -13%
Norges Bank
29
Norges Bank
Norway
$23M -$4.86M -190,194 -14%
Man Group
30
Man Group
United Kingdom
$22.9M +$29.4M +1,150,396 +2,305%
Northern Trust
31
Northern Trust
Illinois
$22.8M -$269K -10,553 -0.9%
Macquarie Group
32
Macquarie Group
Australia
$19.4M -$3.39M -132,808 -12%
Charles Schwab
33
Charles Schwab
California
$18.3M +$543K +21,274 +2%
Citadel Advisors
34
Citadel Advisors
Florida
$16.1M +$17.6M +689,473 +448%
Morgan Stanley
35
Morgan Stanley
New York
$15.1M +$5.18M +203,009 +34%
ZCI
36
Zevenbergen Capital Investments
Washington
$14.8M +$5.31M +207,757 +37%
GF
37
Gabelli Funds
New York
$14M +$2.39M +93,500 +15%
SAM
38
Silvercrest Asset Management
New York
$13.9M -$174K -6,828 -0.9%
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$13.8M +$144K +5,625 +0.8%
Franklin Resources
40
Franklin Resources
California
$12.4M +$2.36M +92,496 +17%
Qube Research & Technologies (QRT)
41
Qube Research & Technologies (QRT)
United Kingdom
$12.2M +$13.6M +532,474 +504%
CCM
42
Camber Capital Management
Massachusetts
$11.9M +$16M +625,000 New
EAM
43
Eagle Asset Management
Florida
$11.9M -$3.29M -128,706 -17%
Jennison Associates
44
Jennison Associates
New York
$11.7M +$15.6M +611,816 New
Goldman Sachs
45
Goldman Sachs
New York
$11.7M -$1.61M -62,964 -9%
SCA
46
Summit Creek Advisors
Minnesota
$10.4M -$780K -30,527 -5%
Bank of America
47
Bank of America
North Carolina
$9.85M +$2.86M +111,895 +28%
HCM
48
Hodges Capital Management
Texas
$9.67M +$789K +30,889 +7%
GT
49
Glenmede Trust
Pennsylvania
$9.64M +$75.2K +2,945 +0.6%
RPA
50
Rock Point Advisors
Vermont
$9.41M +$3.6M +140,780 +40%

EVH Hedge Fund Activity: Q2 2024 in Review

243 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q2 2024, worth a combined $2.48B — down 40% from $4.12B a quarter earlier.

Sellers outnumbered buyers: 51 funds closed out of EVH and 45 opened new positions — a net loss of 6 holders — while 74 trimmed existing stakes and 102 added.

The largest buyer was RA Capital Management, adding an estimated $71M. The largest seller was Fidelity Investments, cutting an estimated $114M.

  • 243 institutional investors held Evolent Health (EVH) as of Q2 2024, down from 251 in Q1 2024.
  • Funds reported $2.48B of Evolent Health stock for Q2 2024, down 40% quarter-over-quarter.
  • 45 funds opened new Evolent Health positions in Q2 2024 and 51 closed out, a net change of -6 holders.
  • The largest Evolent Health buyer in Q2 2024 was RA Capital Management, an estimated $71M added.
  • The largest Evolent Health seller in Q2 2024 was Fidelity Investments, an estimated $114M sold.

Based on aggregated 13F filings for Q2 2024.